IOL Chemicals Q1 FY27: Revenue up 37%, PAT up 90%

Key takeaway from the Q1 FY27 earnings call

IOL Chemicals and Pharmaceuticals Limited reported a strong operating quarter for Q1 FY27 (quarter ended June 30, 2026). Standalone revenue from operations rose to ₹756.3 crore, up 37.1% year-on-year from ₹551.7 crore in Q1 FY26. Profitability improved faster than revenue as the company reported EBITDA of ₹111.7 crore, up 60.7% from ₹69.5 crore a year ago. EBITDA margin expanded to 14.6% from 12.4% in Q1 FY26, reflecting operating leverage and product mix. Profit after tax (PAT) came in at ₹64.5 crore, up 89.9% year-on-year versus ₹34.0 crore. PAT margin improved to 8.4% from 6.1%. The earnings call transcript is dated August 13, 2026 and published on August 14, 2026.

Financial performance: revenue, margins, and profits

The quarter’s revenue growth was attributed to healthy demand across key products, improved capacity utilisation, and better realizations. EBITDA growth outpaced revenue, indicating improved operating efficiencies during the period. The company reported EBIT of ₹90.4 crore in Q1 FY27 compared with ₹49.8 crore in Q1 FY26, a year-on-year rise of 81.7%. Alongside PAT growth, the company also disclosed profit before tax (PBT) of ₹86.8 crore, up 90.5% year-on-year from ₹45.5 crore. Management indicated there were no one-offs, with the improvement driven by operations. On a per-share basis, EPS was reported at ₹2.20 for Q1 FY27. Overall, the quarter reflects both scale-up and better conversion of revenue into operating profit.

What changed operationally: utilisation and efficiencies

Management highlighted higher capacity utilisation as a key driver of the margin expansion. Most assets operated at 80% to 95% utilisation during the quarter, as per the call commentary. Higher utilisation typically improves fixed-cost absorption, which can lift margins even when input costs or pricing stay steady. The company also pointed to operational efficiencies that supported profitability. The narrative in the transcript linked the margin improvement to operational leverage and product mix. These factors together contributed to a 220 basis point year-on-year increase in EBITDA margin. The company also stated that PAT improvement came without exceptional items, reinforcing that the gains were operational.

Portfolio mix: non-Ibuprofen APIs gain share

A notable disclosure in the earnings discussion was the changing mix within the pharma business. The non-Ibuprofen API portfolio contributed 43% of pharma revenue in Q1 FY27, up from 36% in the earlier period. The company also reported 67% year-on-year growth in this non-Ibuprofen API portfolio. This matters because a broader and growing API mix can reduce dependence on a single molecule. Management linked margin gains partly to non-IBU pharma growth and export realizations. The transcript also indicated that product mix contributed to the improved profitability. This mix shift was presented as an operating driver rather than a one-time benefit.

Exports: higher share of revenue and China approval

Exports rose to 28.5% of revenue in Q1 FY27, up from 24.4% in Q1 FY26. That is a 410 basis point increase in export contribution year-on-year. The company attributed the export improvement to a stronger international business across both segments. A specific regulatory milestone mentioned was NMPA approval for Clopidogrel in China. Management said this approval expands the company’s market reach, supporting its international growth plan. Export realizations were also cited as one of the contributors to EBITDA margin improvement. The higher export mix, alongside portfolio diversification, formed an important part of the quarter’s operating narrative.

Guidance for FY27: growth and margin targets

For FY27, management guided for 15% to 20% revenue growth. The company also guided for an EBITDA margin range of 14% to 15% for FY27. Management expressed confidence in the sustainability of the operating performance referenced in the call. The Q1 FY27 EBITDA margin of 14.6% sits within the guided range, while sequential movement will depend on operating conditions through the year. The company’s messaging in the transcript tied guidance to operational improvements, capacity utilisation, and business mix. These targets frame what investors and analysts may track in subsequent quarters. The guidance was presented as a management outlook rather than a statutory forecast.

Quarterly snapshot table: key metrics (YoY)

Sequential comparison: Q1 FY27 vs Q4 FY26

On a quarter-on-quarter basis, revenue from operations rose to ₹756.3 crore from ₹619.5 crore in Q4 FY26. That translated into a 22.1% QoQ increase in revenue based on the reported comparison table. PAT increased to ₹64.5 crore from ₹53.2 crore in Q4 FY26, a QoQ rise of 21.2%. EBITDA margin was 14.6% in Q1 FY27 versus 15.2% in Q4 FY26, a sequential change of minus 60 bps. PAT margin was 8.4% versus 8.6%, a sequential change of minus 20 bps. This shows that the company scaled revenue meaningfully versus the previous quarter, while margins were broadly stable with a modest pullback from Q4 levels.

What the results suggest for investors and the sector

The quarter’s data points highlight a combination of volume-led growth and better profitability. A key monitoring factor is whether the 80% to 95% utilisation levels across most assets can be maintained as the year progresses. Another factor is whether exports continue to rise as a share of revenue beyond the 28.5% reported in Q1 FY27. The increase in non-Ibuprofen API contribution to 43% of pharma revenue indicates a more diversified pharma mix than the prior period. The NMPA approval for Clopidogrel in China is a concrete regulatory step that management linked to market expansion. FY27 guidance of 15% to 20% revenue growth and 14% to 15% EBITDA margin sets a clear operating framework for upcoming quarters. Investors typically compare actual quarterly margins against the guided range and track mix and realization trends that influence profitability.

Conclusion

IOL Chemicals began FY27 with revenue of ₹756.3 crore and improved profitability, with EBITDA margin at 14.6% and PAT of ₹64.5 crore. The company attributed the quarter’s performance to demand, higher utilisation, operating efficiencies, and a better mix supported by exports. Exports increased to 28.5% of revenue and management cited NMPA approval for Clopidogrel in China as an additional market access milestone. The FY27 guidance of 15% to 20% revenue growth and 14% to 15% EBITDA margin will be a key reference point for the rest of the year. For further detail, the company has directed readers to the full earnings call transcript.